Background-Kirsten ras (Ki-ras) mutations are common in gastrointestinal cancer and one codon 12 mutation, glycine to valine, is particularly aggressive in colorectal cancer. Aims-To investigate if this valine point mutation could be targeted with antisense oligonucleotides and to determine the eYcacy of any antisense/mRNA interaction. Methods-Twenty nine antisense oligonucleotides were screened against target and control Ki-ras RNA in a cell free system and against target and control cell lines in culture. Results-The activity and specificity of the oligonucleotides varied. Results for the individual oligonucleotides were consistent in a cell free model and in cell culture using two diVerent uptake promoters. Only one oligonucleotide was specific in its cleavage of target Ki-ras mRNA in the cell free system and appeared specific in cell culture, although changes in Ki-ras mRNA and protein expression following a single treatment could not be detected. Experiments in the cell free system showed that the point mutation is relatively inaccessible to oligonucleotides. Other sites on the Ki-ras RNA molecule, away from the point mutation, can be targeted more eVectively. Conclusions-Successful targeting of the clinically relevant Ki-ras point mutation with antisense oligonucleotides is diYcult because of RNA structure at the mutated site and is ineYcient compared with other sites on the Ki-ras mRNA. (Gut 2001;48:230-237) 
1
These genetic changes oVer potential as markers of disease for earlier diagnosis, as prognostic indicators, and as therapeutic targets. In a multicentre study of 2721 patients with colorectal cancer, we demonstrated that one of these characteristic genetic defects, the presence of a valine mutation on codon 12 of the Kirsten ras (Ki-ras) gene, increased the risk of death by 43% and was associated with poorer outcome than other Ki-ras mutations. 2 Antisense oligonucleotide therapy aims to block expression of a single protein that is critical for the progression of a specific cancer and relies on the introduction of synthetic oligonucleotides into cells where hybridisationbinding-to specific complementary target mRNA by Watson-Crick base pairing can occur. 3 Such hybridisation can inhibit protein expression through a number of mechanisms, 4 5 one of which is activation of RNase H, an ubiquitous intracellular enzyme. RNase H cleaves antisense/RNA duplexes destroying the RNA but leaving the antisense oligonucleotide free to bind to further complementary mRNA. If the antisense target is unique to the cancer and absent in normal cells, it is hoped that the antisense molecule will have no activity in normal cells. Preliminary clinical studies have demonstrated that treatment with antisense can be a safe relatively non-toxic strategy and there is already evidence of eYcacy. [6] [7] [8] Antisense oligonucleotide design is critical for eYcacy as the base pairing which maintains the secondary and tertiary structure of the target RNA may prevent hybridisation of some antisense molecules. 9 The eVect of RNA structure on oligonucleotide binding is diYcult to predict and small diVerences in oligonucleotide structure can lead to large diVerences in hybridisation eYciency. Therefore, for each target RNA, large numbers of oligonucleotides need to be screened to identify which is most eYcacious. 10 11 Alternatively, libraries of random oligonucleotides can identify the most accessible regions of RNA. 12 There are no studies that have systematically investigated the eYcacy of antisense treatment directed at a clinically relevant point mutation in gastrointestinal cancer. We investigated if one specific Ki-ras point mutation associated with a poor outcome could be targeted with antisense oligonucleotides. Our aim was to screen a series of antisense oligonucleotides to identify an active molecule with a bona fide antisense mechanism of action.
Methods

CELL LINES
SW480 human primary colorectal adenocarcinoma cells, with a homozygous mutation at codon 12 (glycine to valine: GGT→GTT) were used as the target cell culture model. Two other human colorectal carcinoma cell lines, HT29 (wild-type Ki-ras alleles at codon 12/13-mutated codon 61) and LoVo (heterozygous codon 13 GGC→GAC aspartate muta-tion) provided control cell line models. Ki-ras genotypes were confirmed by DNA sequencing. 13 Cell lines were maintained in Dulbecco's modified eagle medium supplemented with 50 units/ml penicillin, 50 mg/ml streptomycin, 2 mM L-glutamine and 10% heat inactivated fetal calf serum in a non-humidified 5% CO 2 atmosphere incubator at 37°C.
CELL FREE RNase H ASSAY Exon 1 of Ki-ras was amplified from SW480, HT29, and LoVo genomic DNA using primers: 5'-CAGTCAGTAAGCTTCCTAA TACGACTCACTATAGGGAGTATAAGGC CTGCTGAAAATGACTGAATATAA-3' (T7 bacteriophage promoter) and 5'-CAGT CAGTGAATTCACA AGATTTACCTCTAT TGTTGGATCATAT-3' at 35 cycles at 92°C for one minute, 60°C for one minute, and 72°C for two minutes. RNA was produced by in vitro transcription with T7 bacteriophage RNA polymerase and labelled at its 3' terminus with T4 bacteriophage RNA ligase and 32 pCp.
14 A master mix (4 µl/reaction)-50 000 Cerenkov counts/minute/reaction of heat quenched 3' labelled RNA, 1 µl/reaction 5× buVer (700 mmol KCl, 125 mmol Tris, pH 7.6, 50 mM MgCl 2 ), 0.13 units/reaction Escherichia coli RNase H (Pharmacia), and 5 units/reaction rRNase inhibitor-was added to 1 µl of 1 µM oligonucleotide at 37°C for 30 minutes. Reactions were terminated by addition of 5 µl of gel loading buVer (10 M urea, 1.5× TBE, 0.015% w/v bromophenol blue, 0.015% w/v xylene cyanol) at 68°C for 10 minutes. Cleavage products were analysed by electrophoresis on a denaturing 8% polyacrylamide/7 M urea gel followed by direct autoradiography.
A similar approach was used to prepare a 3' labelled RNA encompassing the first three coding exons of Ki-ras mRNA. This RNA was incubated as above with a range of oligonucleotide concentrations (1-1000 nM) over a 30 minute time course. 15 It was also used to screen for accessible sites after incubation with 2.5 µg of a heat quenched library of random sequence oligonucleotides and 0. 13 The bacterial toxin streptolysin O was used to permeabilise cells in monolayer culture by amending a protocol for cells in suspension. 16 Conditions allowing temporary permeabilisation of cell membranes by streptolysin O without compromising long term cell viability were optimised using an MTT assay 17 and by coincubation with propidium iodide. 18 Cells were seeded on day 0 to achieve 80% confluency at harvest. On day 1, media was removed and cells were washed twice with Dulbecco's modified eagle medium. Each well was treated with a 15 µl solution containing 10 µM antisense oligonucleotide, and 7.5 units/ml streptolysin O preactivated at 4°C for one hour with 5 mM dithiothreitol and the volume made up with Dulbecco's modified eagle medium. Cells assayed as controls were treated with an equivalent volume of media or control oligonucleotide. Cells were incubated for 30 minutes at 37°C, washed twice, and then serum containing media was replaced.
Cationic lipid transfection was used as an alternative to streptolysin permeabilisation. A screen of the Pfx lipid series (Invitrogen) identified Pfx-3 (1:1 mixture of a proprietary cationic lipid and DOPE at 2 mg/ml) as the optimal lipid for transfection of SW480 cells. Cells were seeded on day 0 as described above, on day 1 a solution of Pfx-3 24 µg/ml was made up in serum free OptiMEM medium (Gibco Life Technologies, Paisley, UK) with L-glutamine 2 mM and CaCl 2 100 mg/l. A 400 nM solution of oligonucleotide was also prepared in OptiMEM. Equal volumes of the two solutions were mixed and incubated at room temperature while the cells were washed twice in OptiMEM. Transfection solution was added to each well. Cells were incubated for four hours at 37°C, the transfection solution was removed, and serum containing medium replaced. Uptake of FITC labelled oligonucleotide was detected at four hours in approximately 80% of lipid treated cells. This eVect persisted for at least 24 hours. There was almost no detectable fluorescence in cells treated without lipid (data not shown).
CELL VIABILITY AND PROLIFERATION ASSAYS
Viability was assayed by an MTT reaction and proliferation was measured by 3 H thymidine incorporation. 3 H thymidine was diluted in sterile phosphate buVered saline at 0.1 mCi/ml and 10 µl were added to each treated microwell 24 hours before the cells were harvested. The cells were washed with fresh media, trypsinised, and trapped on filter mats (Skatron) using an Inotech cell harvester. Filters were fixed in 100% ethanol, dried, and 3 H thymidine incorporation was measured on an Inotech plate reader in a 90% argon/10% methane gas stream.
ANALYSIS OF Ki-ras EXPRESSION
mRNA Single stranded high specific activity antisense RNA probes for human GAPDH (exons [5] [6] [7] [8] and Ki-ras (exons 1-3) were prepared by in vitro transcription in the presence of [a-
14 RNase protection analysis of mRNA was performed directly in cell lysates, 5×10 5 cells/assay, using a Direct Protect assay (Ambion, USA). Protected fragments were separated by electrophoresis on denaturing 8% polyacrylamide/7 M urea gels and detected by direct autoradiography.
Protein
Cells were recovered, washed twice, and resuspended at 10 7 /ml in ice cold lysis buVer (10 ml: 50 mM Tris HCl, 150 mM NaCl, pH 7.5, 1% (v/v) Nonindet P-40, 1% (w/v) sodium dodecyl sulphate, ×1 protease inhibitors; Complete mini tablets, Boehringer, Mannheim, Germany) passed through a 25 gauge needle and left on ice for 20 minutes. The suspension was centrifuged at 16 000 g at 4°C for 20 minutes. The supernatant was removed, a 25 µl aliquot was used for protein estimation, and the rest was stored at −70°C. Protein concentration was determined by Lowry assay (BioRad). 19 Equal amounts of protein (100 µg) and rainbow molecular weight markers (Amersham Life Sciences, Buckinghamshire, UK) were resolved by electrophoresis on a 12.5% polyacrylamide gel 20 and electrotransferred to hybond-c nitrocellulose. 21 Ki-ras protein was detected using primary antihuman c-Ki-ras mouse antibody (Oncogene Research Products, Cambridge, Massachusetts, USA) specific for wild-type and mutant protein. 22 23 Immunoblots were blocked with 5% non-fat milk in TBST (20 mM Tris HCl, pH 8.0, 150 mM NaCl, 0.05% Tween 20) and incubated at room temperature for one hour with 5 µg/ml antibody (in 1% gelatine and TBST). C-raf-1 protein was detected using 0.25 µg/ml mouse antihuman c-Raf-1 antibody (Transduction Laboratories, Lexington, USA) for two hours at room temperature in 5% non-fat milk TBST (pH 7.5).
11 Specific antigen-antibody interaction was detected with a horseradish peroxidase conjugated antimouse IgG using enhanced chemiluminescence western blotting detection reagents (Amersham Life Sciences).
OLIGONUCLEOTIDES
Twenty nine diVerent 13-17mer oligonucleotides (and their reverse sequence controls) complementary to a region encompassing the codon 12 glycine to valine Ki-ras point mutation were synthesised (Genosys, Cambridge, UK) and purified by high pressure liquid chromatography (fig 1) . Oligonucleotides larger than a 17mer are not eYcient at discriminating point mutations. 24 To minimise the potential non-specific toxicity observed with phosphorothioate oligonucleotides, we initially used oligonucleotides with a phosphodiester backbone and two terminal phosphorothioate linkages at the 3' and 5' termini. [25] [26] [27] Capped molecules also increase stability compared with pure phosphodiester molecules. 28 29 Several oligonucleotides were also synthesised as full phosphorothioates. The 17mer randomer oligonucleotides for cell free studies were synthesised with a pure phosphodiester backbone. The antisense oligonucleotide PR4 was a phosphorothiated 17mer targeted against nucleotides 373-409.
Results
ANTISENSE TO Ki-ras mRNA IN A CELL FREE ASSAY
To determine if antisense oligonucleotides could show specificity for a point mutation, each oligonucleotide was incubated with RNase H and a 32 P end labelled RNA corresponding to exon 1 of Ki-ras mRNA. This RNA either contained the target codon 12 valine mutation, a control codon 13 mutation, or a control wild-type sequence.
Incubation of oligonucleotides, the RNA target sequence, and RNase H resulted in up to five cleavage products although some oligonucleotides were inactive (fig 2A, B) . The intensity of individual cleavage products varied. However, the relative intensity of cleavage, size, and number of products were reproducible. All the 13mers and 14mers were inactive, the 15mers showed poor activity while the 16mers induced increased cutting (fig 2A) . However, the 17mers were the most active ( fig  2B) . It was apparent that the oligonucleotides skewed 5' to the mutation were the most active. Those skewed 3' were inactive.
Comparison with RNase T 1 sequencing lanes suggested that the products with oligonucleotide 17.2 in the SW480 lane represented RNase H cleavage around the mutation site (data not shown). Incubation with a control RNA carrying the aspartate 13 mutation resulted in the detection of cleavage products with oligonucleotides 17.1, and 17.3-17.5, and with the wild-type RNA also resulted in some cleavage except with 17.2. Thus oligonucleotide 17.2 appeared to be highly specific at inducing RNase H cleavage of the target RNA.
ANTISENSE TO Ki-ras mRNA IN CELL CULTURE
To compare the eYcacy of the oligonucleotide series in the cell lines we used a direct permea- bilisation approach which was equally eYcient in all three lines (data not shown). Viability, assessed using the MTT assay of mitochondrial activity, was not aVected in any consistent way at one, three, five, or seven days in either SW480 or LoVo cells (data not shown) when cells were treated with a single dose of streptolysin O and each of the 29 antisense oligonucleotides or streptolysin O alone. Therefore, the eVect of treatment was examined further using a proliferation assay.
For Figure 3 illustrates data from the 17mer series of oligonucleotides. The greatest specificity and eYcacy was seen with oligonucleotide 17.2 which induced a 32.2% (SEM 0.06) reduction in thymidine incorporation in SW480 cells after a single dose but had minimal eVects on the HT29 (wild-type) and LoVo (aspartate 13) control cell lines.
Data obtained with streptolysin O permeabilisation were followed up in SW480 cells using a cationic lipid to compare the 17mer antisense oligonucleotides with their control reverse sequence oligonucleotides. The three cell lines required diVerent lipid formulations to achieve eYcient transfection of DNA and therefore direct comparisons between cell lines using lipids could not be made.
When 3 H thymidine incorporation was measured in cells treated with antisense or reverse sequence, results similar to those using streptolysin O were obtained (fig 4) . Oligonucleotide 17.2 again seemed to be the most eVective compared with its reverse sequence Figure 2 (A and the other antisense designs. No activity was detected if 17.2 was added to media without enhanced uptake by permeabilisation or transfection (data not shown).
Ki-ras EXPRESSION FOLLOWING ANTISENSE TREATMENT IN CELLS
To confirm the specificity of the antisense eVect seen with 17.2 in all of our systems, we examined Ki-ras mRNA and protein levels following antisense treatment. Changes in Ki-ras mRNA levels have been reported to occur 24 hours after antisense treatment. 30 However, we were unable to detect changes in Ki-ras mRNA levels in SW480 cells 24 hours after treatment with the 17mer oligonucleotides transfected into cells using cationic lipids (fig 5A) . One possible explanation for the absence of eVect on Ki-ras mRNA expression was instability of the chimeric oligonucleotide. However, this was discounted as a fully phosphorothioated version of 17.2 was equally ineVective at reducing Ki-ras mRNA expression ( fig 5B) . In addition, we found that an active Ki-ras antisense that recognises wild-type Ki-ras could reduce Ki-ras expression eVectively and specifically at 24 hours, demonstrating that our model system was capable of producing and detecting antisense eVects ( fig 5C) .
An alternative explanation was that the eVects we detected were due to steric blocking of the translation of Ki-ras mRNA, which would reduce protein levels without altering mRNA levels. However, no changes in Ki-ras protein expression were detected in any cells assayed at 8, 16, 24, 36, or 48 hours following oligonucleotide treatment (fig 6) . It is also unlikely that changes in Ki-ras protein levels occurred earlier than eight hours and were missed. The half life of Ki-ras protein is not known. However, when cycloheximide, a general protein synthesis inhibitor, was added (50 µg/ml) to SW480 cells in culture and Ki-ras protein levels were assayed at various time points up to 54 hours, detectable Ki-ras protein did not disappear until 30 hours later (data not shown). It is likely that cycloheximide arrest of protein synthesis is more abrupt and possibly more complete than would be seen with the best antisense therapy. Therefore, it would seem reasonable that if an antisense eVect is occurring, it will be seen at least 30 hours after treatment.
SCREENING OF Ki-ras mRNA FOR SITES ACCESSIBLE TO OLIGONUCLEOTIDES AND RNase H These observations implied that the point mutated target site on Ki-ras mRNA was not easily accessible, thus perhaps explaining the modest eVect on proliferation seen and lack of detectable eVect on mRNA and protein expression. We noted that the best oligonucleotide (17.2) required an approximate 500-fold excess of oligonucleotide to achieve partial cleavage of the target exon 1 substrate RNA.
Computer mapping suggests that codon 12 of Ki-ras lies in a structured base paired region of the mRNA (fig 7) . The glycine to valine point mutation has a minimal eVect on this structure, only slightly weakening the base 
Figure 5 (A) RNase protection analysis of Ki-ras and GAPDH expression following 24 hour treatment of SW480 cells with oligonucleotides 17.1-17.7 and their respective reverse sequence controls (scr). (B) Treatment of SW480 cells for 24 and 48 hours with the end capped and fully phosphorothiated versions of oligonucleotide 17.2 (C) Ki-ras antisense (PR4) recognises wild-type Ki-ras eVectively and specifically reduces Ki-ras expression at 24 hours.
Ki-ras pairing and opening a small loop within this region. However, computer predictions of RNA structure can be unreliable and therefore the accessibility of the structure around the point mutation to oligonucleotides and RNase H was investigated using a cell free screen. An end labelled RNA corresponding to the first three exons of the Ki-ras mRNA was incubated with a random library of 17mer oligonucleotides and RNase H. The random library of oligonucleotides contained a representation of all possible 17mer sequences. This assay therefore allows only 17mers complementary to the most accessible regions of the RNA to bind and activate RNase H. A parallel incubation with sequence specific RNases allowed precise positioning of cut sites induced by the randomer library. A number of sites were preferentially digested, although the codon 12 point mutation was not one of them (fig 8) . This suggested that the target point mutation was not easily accessible either to oligonucleotides or RNase H.
We compared the activity of 17.2 and oligonucleotide PR4-which targeted one of the preferentially digested sites-in the cell free assay against the exons 1-3 Ki-ras mRNA containing the valine 12 point mutation. At a single time point taken from the kinetic analysis, it was clear that 17.2 was far less eVective than PR4, requiring 100 times more oligonucleotide to achieve a similar rate of cutting (fig 9) .
Discussion
In this study, we screened the eYcacy of a large number of antisense molecules at inducing RNase H cleavage of a clinically important target, a point mutated Ki-ras mRNA. DiVerent molecular structures were designed by changing the oligonucleotide length and skewing the sequence complementary to the point mutation in either direction away from the centre.
Our most eVective oligonucleotide needed to penetrate the cell membrane to obtain eYcacy and was completely inactive when added directly to the tissue culture media in the absence of cell permeabilisation or cationic lipid. In the presence of both uptake promoters, the oligonucleotides gave similar results. However, we saw no eVect on cell viability, either in target or control cells, although we did see a consistent although modest eVect on cell proliferation using 3 H thymidine incorporation assays.
It has been suggested that oligonucleotides which have 3' or 5' terminal thymidines may interfere with 3 H thymidine incorporation and hence give misleading results. 31 We saw no evidence for this. Indeed, the most eVective oligonucleotide, 17.2, had only one thymidine located six nucleotides from the 3' end. In addition, antisense and reverse sequence control oligonucleotides with the same base composition did not produce equivalent eVects and the results with 3 H thymidine incorporation in cell culture closely matched the results obtained in the cell free system.
Failure to demonstrate change in protein or RNA expression could be because the capped oligonucleotides were insuYciently stable to maintain an eVect on RNA or protein.
However, data from elsewhere suggest that the stability of end capped oligonucleotides in culture is not a significant issue 28 32 and we still saw no eVect on mRNA expression when a fully phosphorothioated 17.2 was used in cell culture. Our model system was capable of detecting antisense eVects as an oligonucleotide designed to target a more accessible site completely inhibited Ki-ras expression. This suggested that the mutation site was not easily targeted and that the modest eVects on prolif- All of these data support the contention that the RNA structure of the target region can influence oligonucleotide eYcacy, as in our models the oligonucleotides skewed 3' to the mutation were particularly ineVective whereas the most eVective oligonucleotide was skewed 5' to the point mutation. When hybridising to the RNA, the more active oligonucleotides bound sites encompassing the stem loop carrying the point mutation, an adjacent stem loop, and the junction between these structures. In contrast, the most inactive molecules were restricted to the stem loop carrying the point mutation.
There is no doubt that targeting a point mutation is possible. 24 33-39 No previous study has attempted to target a Ki-ras mutation systematically, although two studies have used two oligonucleotides chosen at random to target Ki-ras mutations and their results add weight to our findings. One used a 17mer antisense to target a glycine to serine codon 12 Ki-ras mutation. 40 Antisense specific antiproliferative eVects with a 4 µM IC 50 were demonstrated, but at the IC 50 there was no significant decrease in Ki-ras protein expression, which was achieved only by multiple dosing at a higher dose. A second study 41 used a 16mer to target the codon 12 valine mutation but found it to have no antisense related activity at a dose of up to 200 µM. This oligonucleotide was equivalent to our oligonucleotide 16.2 which we also found ineVective.
In summary, to optimise antisense activity it is necessary to screen oligonucleotides of diVerent sequence for activity. It is necessary to elicit whether eVects seen are due to nonspecific actions or specific antisense activity. In these series of experiments, a molecule was identified which appeared to have greater activity and increased specificity for its target. However, we also showed that using currently available backbone chemistry, targeting codon 12 is diYcult while a oligonucleotide directed at a more accessible site induced the expected large reduction in expression. As a defect has been identified in the Ki-ras mediated pathway in 95% of early colorectal cancers, but involves a mutation in Ki-ras itself in only 40% of tumours, 2 42 targeting one of the accessible sites may be a more practical approach. An alternative approach would be the development of oligonucleotide backbone chemistries capable of destabilising RNA structure around codon 12. The rationale being that the mutated protein targeted is of such clinical significance and that the grail of avoiding non-specific toxicity is one that should still be pursued vigorously.
